Numinus Provides Bi-Weekly Update on Annual Filings
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) provided an update regarding its previously announced management cease trade order (MCTO). The order, granted by the British Columbia Securities Commission on December 2, 2024, restricts the CEO and CFO from trading company securities until the Annual Filings are completed. The delay affects the company's audited annual financial statements, MD&A, and annual information form for the year ended August 31, 2024.
During this period, Numinus will suspend share buy-back activities and won't issue or acquire securities from insiders or employees. The company expects to complete the Annual Filings by January 28, 2025. Shareholder trading remains unaffected, and the company will provide bi-weekly updates through news releases on SEDAR+.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) ha fornito un aggiornamento riguardo all'ordine di cessazione del commercio da parte della direzione (MCTO) precedentemente annunciato. L'ordine, concesso dalla British Columbia Securities Commission il 2 dicembre 2024, limita il CEO e il CFO dal trading dei titoli della società fino al completamento delle Dichiarazioni Annuali. Il ritardo influisce sui bilanci annuali auditati dell'azienda, sulla relazione di gestione e analisi (MD&A) e sul modulo informativo annuale per l'anno terminato il 31 agosto 2024.
Durante questo periodo, Numinus sospenderà le attività di riacquisto di azioni e non emetterà né acquisterà titoli da dirigenti o dipendenti. L'azienda prevede di completare le Dichiarazioni Annuali entro il 28 gennaio 2025. Il trading degli azionisti rimane non influenzato e l'azienda fornirà aggiornamenti bisettimanali tramite comunicati stampa su SEDAR+.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) proporcionó una actualización sobre la orden de cese de comercio de gestión (MCTO) previamente anunciada. La orden, otorgada por la British Columbia Securities Commission el 2 de diciembre de 2024, restringe al CEO y al CFO de operar con valores de la empresa hasta que se completen las Declaraciones Anuales. El retraso afecta los estados financieros anuales auditados de la empresa, el MD&A y el formulario de información anual para el año que terminó el 31 de agosto de 2024.
Durante este período, Numinus suspenderá las actividades de recompra de acciones y no emitirá ni adquirirá valores de directivos o empleados. La empresa espera completar las Declaraciones Anuales para el 28 de enero de 2025. El comercio de los accionistas no se verá afectado y la empresa proporcionará actualizaciones quincenales a través de comunicados de prensa en SEDAR+.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF)는 이전에 발표된 관리 거래 중지 명령(MCTO)에 대한 업데이트를 제공했습니다. 이 명령은 2024년 12월 2일 브리티시컬럼비아 증권위원회에 의해 부여되었으며, CEO와 CFO가 연간 신고서가 완료될 때까지 회사 증권 거래를 제한합니다. 이 지연은 2024년 8월 31일로 끝나는 회계연도의 감사 연간 재무 제표, 관리 및 분석(MD&A), 연간 정보 양식에 영향을 미칩니다.
이 기간 동안, Numinus는 자사주 매입 활동을 중단하고 내부자 또는 직원으로부터 증권을 발행하거나 인수하지 않을 것입니다. 회사는 2025년 1월 28일까지 연간 신고서를 완료할 것으로 예상하고 있습니다. 주주 거래에는 영향이 없으며, 회사는 SEDAR+를 통해 보도 자료로 격주 업데이트를 제공할 것입니다.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) a fourni une mise à jour concernant son ordonnance de cessation de commerce de gestion (MCTO) précédemment annoncée. L'ordonnance, accordée par la British Columbia Securities Commission le 2 décembre 2024, restreint le PDG et le CFO de négocier des titres de la société jusqu'à ce que les Déclarations Annuelles soient complétées. Le retard affecte les états financiers annuels audités de l'entreprise, le MD&A, et le formulaire d'information annuel pour l'année se terminant le 31 août 2024.
Durant cette période, Numinus suspendra ses activités de rachat d'actions et n'émettra ni n'acquerra de titres provenant d'initiés ou d'employés. L'entreprise s'attend à compléter les Déclarations Annuelles d'ici le 28 janvier 2025. Le commerce des actionnaires demeure sans impact, et l'entreprise fournira des mises à jour bi-hebdomadaires par le biais de communiqués de presse sur SEDAR+.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) hat ein Update bezüglich der zuvor angekündigten Management-Handelsstopp-Verfügung (MCTO) bereitgestellt. Die Verfügung, die am 2. Dezember 2024 von der British Columbia Securities Commission erlassen wurde, beschränkt den CEO und CFO darin, Unternehmenswerte zu handeln, bis die Jahresberichte abgeschlossen sind. Die Verzögerung betrifft die geprüften Jahresabschlüsse des Unternehmens, den Lagebericht und die jährliche Informationsformulare für das zum 31. August 2024 ended Jahr.
In dieser Zeit wird Numinus die Aktienrückkaufaktivitäten aussetzen und keine Wertpapiere von Insidern oder Mitarbeitern ausgeben oder erwerben. Das Unternehmen erwartet, die Jahresberichte bis zum 28. Januar 2025 abzuschließen. Der Handel der Aktionäre bleibt unbeeinflusst und das Unternehmen wird alle zwei Wochen über Pressemitteilungen auf SEDAR+ aktualisieren.
- None.
- Management cease trade order (MCTO) imposed due to delayed annual filings
- Suspension of share buy-back program
- Restriction on securities transactions with insiders and employees
- Unexpected delays in completing annual financial statements
Further to the Company's news release dated December 3, 2024 (the "Announcement"), the Company's principal regulator, the British Columbia Securities Commission (the "Commission"), granted the MCTO on December 2, 2024, under National Policy 12-203 – Management Cease Trader Orders ("NP 12-203"). Pursuant to the MCTO, the Chief Executive Officers and the Chief Financial Officer of the Company may not trade in securities of the Company until such time as the Company files the Annual Filings and the Commission revokes the MCTO. During this period, the Company will cease any share buy-back activities under its normal course issuer bid, and has undertaken not to, directly or indirectly, issue or acquire securities from an insider or employee of the Company.
The MCTO does not affect the ability of shareholders to trade their securities.
The Company's Board of Directors and management are continuing to work with its accounting team to prepare the Annual Filings as soon as practicable. The delay in filing the Annual Filings is a result of unexpected delays experienced by the Company. It is the Company's reasonable expectation that the Annual Filings will be finalized by January 28, 2025.
The Company will issue a news release announcing completion of filing of the Annual Filings at such time as they are completed and filed. Until the Company files the Annual Filings, it will comply with the alternative information guidelines set out in under NP 12-203 including issuing bi-weekly default status reports by way of news releases, which will be filed on SEDAR+.
In addition, the Company confirms that since the date of the Announcement: (i) there has been no failure by the Company in fulfilling its stated intentions with respect to satisfying the provisions of the alternative information guidelines set out in NP 12-203; (ii) there has not been any other specified default by the Company under NP 12-203; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no other material information concerning the affairs of the Company that has not been generally disclosed.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms of depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. Learn more at www.numinus.com and follow us on LinkedIn, Facebook, and Instagram.
Forward Looking Statements
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. In particular, and without limitation, this news release contains forward-looking statements respecting the Company's reasonable expectation that the Annual Filings will be finalized by January 28, 2025 and the Company's compliance with the MCTO and NP 12-203. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements, including the results of further research into MDMA, if any, the FDA and other regulators' decisions in respect of MDMA and other psychedelic medications, restrictions that may be placed on the use of psychedelic compounds by regulatory authorities; safety and efficacy of psychedelic-assisted therapy; acceptance, uptake and commercialization of psychedelic assisted therapy, if any; dependence on obtaining regulatory approvals, and other risks that are set forth in our annual information form dated November 29, 2023, and available on SEDAR at www.sedarplus.ca. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Numinus does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.
View original content:https://www.prnewswire.com/news-releases/numinus-provides-bi-weekly-update-on-annual-filings-302332786.html
SOURCE Numinus Wellness Inc.
FAQ
When will Numinus (NUMIF) complete its delayed Annual Filings for 2024?
How does the MCTO affect Numinus (NUMIF) shareholders?
What restrictions does the MCTO place on Numinus (NUMIF)?
What caused the delay in Numinus (NUMIF) Annual Filings for 2024?
